Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests

References

• World Health Organization. Cancer. Media Centre. 2014. Available from: www.who.int/mediacentre/factsheets/fs297/en/ [Last accessed 04 March 2015]
   Google Scholar
• American Cancer Society. What are the key statistics about lung cancer? 2014. Available from: www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics [Last accessed 03 April 2015]
   Google Scholar
• American Cancer Society. Non-small cell lung cancer survival rates by stage. 2014. Available from: www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates [Last accessed 03 April 2015]
   Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2(8):706-14
   PubMed Web of Science ®Google Scholar
• Chansky K, Sculier JP, Crowley JJ, et al. The international association for the study of lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4(7):792-801
   PubMed Web of Science ®Google Scholar
• Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010;5(2):220-8
   PubMed Web of Science ®Google Scholar
• Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-15
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 2008;26(31):5043-51
   PubMed Web of Science ®Google Scholar
• Graziano SL, Gu L, Wang X, et al. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 2010;5(6):810-17
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9
   PubMed Web of Science ®Google Scholar
• Vilmar AC, Santoni-Rugiu E, Sørensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010;21(9):1817-24
   PubMed Web of Science ®Google Scholar
• Li XQ, Li J, Shi SB, et al. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 2009;24(4):230-7
   PubMed Web of Science ®Google Scholar
• Subramanian J, Simon R. Gene expression–based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102(7):464-74
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98(24):13790-5
   PubMed Web of Science ®Google Scholar
• Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62(11):3005-8
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Richards WG, Sugarbaker DJ, et al. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 2003;12(9):905-10
   PubMed Web of Science ®Google Scholar
• Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816-24
   PubMed Web of Science ®Google Scholar
• Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. Public Libr Sci Med 2006;3(12):e467
   Google Scholar
• Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25(35):5562-9
   PubMed Web of Science ®Google Scholar
• Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Shedden K, Taylor JM, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14(8):822-7
   PubMed Web of Science ®Google Scholar
• Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15(1):284-90
   PubMed Web of Science ®Google Scholar
• Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA 2009;106(8):2824-8
   PubMed Web of Science ®Google Scholar
• Collisson EA, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511(7511):543-50
   PubMed Web of Science ®Google Scholar
• Hammerman PS, Lawrence MS, Voet D, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25
   PubMed Web of Science ®Google Scholar
• Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379(9818):823-32
   PubMed Web of Science ®Google Scholar
• Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008;14(17):5565-70
   PubMed Web of Science ®Google Scholar
• Kratz JR, Van den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. J Am Med Assoc 2012;308(16):1629-31
   Web of Science ®Google Scholar
• Kratz JR, Tham PT, Mulvihill MS, et al. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol 2013;22(2):65-9
   PubMed Web of Science ®Google Scholar
• National Human Genome Research Institute. Reimbursement Models to Promote Evidence Generation and Innovation for Genomic Tests. Available from: www.genome.gov/27552210 [Last accessed 24 October 2012]
   Google Scholar
• Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. Bio Med Cent Genomics 2008;1:11
   PubMed Web of Science ®Google Scholar
• Starmans MH, Krishnapuram B, Steck H, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008;99(11):1884-90
   PubMed Web of Science ®Google Scholar
• Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 2013;19(22):6261-71
   PubMed Web of Science ®Google Scholar
• Bueno R, Hughes E, Wagner S, et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015;10(1):67-73
   PubMed Web of Science ®Google Scholar
• Carr SR, Schuchert MJ, Pennathur A, et al. Impact of tumor size on outcomes after anatomic lung resection for stage IA non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg 2012;143(2):390-7
   PubMed Web of Science ®Google Scholar
• Bueno R. The 15th world conference on lung cancer. Validation of a 46-gene expression signature in early-stage non-small-cell lung cancer. Lecture conducted from Sydney; Australia: 2013
   Google Scholar
• Myriad Genetics, Inc. Myriad myPlanTM lung cancer test launched to leading oncologists test accurately identifies which patients may need post-surgical chemotherapy. Available from: http://investor.myriad.com/releasedetail.cfm?releaseid=801093 [Last accessed 29 October 2013]
   Google Scholar
• Myriad Genetics, Inc. myPlanTM Specimen Instructions. Available from: https://s3.amazonaws.com/myriad-web/myriadpro.com/publications/116262_MyPlanInstruc_proof.pdf [Last accessed 14 August 2014]
   Google Scholar
• Genome web. MDx/CDx Focus: myriad launches myPlan lung cancer test; NY DOH grants permit for pathway fit; and More. Available from: www.genomeweb.com/clinical-genomics/mdxcdx-focus-myriad-launches-myplan-lung-cancer-test-ny-doh-grants-permit-pathwa [Last accessed 30 October 2013]
   Google Scholar
• Tang H, Xiao G, Behrens C, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 2013;19(6):1577-86
   PubMed Web of Science ®Google Scholar
• Life Technologies. PervenioTM Lung Cancer RS Specimen Requirements. Available from: www.lifelabdx.com/documents/Pervenio%20Lung%20TRF.pdf [Last accessed 15 August 2014]
   Google Scholar
• Adjuvant Chemotherapy in Patients With High Risk Stage I Non-squamous Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01817192
   Google Scholar